Twelve weeks of ombitasvir/paritaprevir/r and dasabuvir without ribavirin is effective and safe in the treatment of patients with HCV genotype 1b infection and compensated cirrhosis: results from a real-world cohort study
- Chamorro-de-Vega, E.
- Gimenez-Manzorro, A.
- Rodriguez-Gonzalez, C.-G.
- Escudero-Vilaplana, V.
- De Lorenzo-Pinto, A.
- Iglesias-Peinado, I.
- Herranz-Alonso, A.
- Sanjurjo Saez, M.
ISSN: 1744-764X, 1474-0338
Argitalpen urtea: 2018
Alea: 17
Zenbakia: 3
Orrialdeak: 235-241
Mota: Artikulua